Anti-EGFR antibody was expected to be effective against GC, because KRAS mutations are infrequent molecular events [28,29], and KRAS-mutated GC was not affected by capeciatbine+cisplatin with or without cetuximab in our study. This evidence concerns the gene KRAS and gastric cancer.